IMMUNOTHERAPIES MOVING FORWARD

COMPANY

Agilvax discovers and develops targeted cancer stem cell immunotherapies and vaccines with its proprietary virus-like particle (VLP) platform technology. Agilvax's lead cancer stem cell immunotherapy, AX09, is first being tested a potential therapeutic for triple-negative breast cancer. Triple negative breast cancer is extremely aggressive with higher rates of recurrence and overall poorer outcome than other forms of breast cancer. With no targeted therapies currently available there is a critical need for the development of therapeutics for patients impacted by triple-negative breast cancer. AX09 is composed of a VLP that displays a specific portion of a protein, xCT, that has been reported to be overexpressed in breast cancer stem cells and contributes to chemotherapeutic drug resistance and metastasis. Agilvax is currently performing extensive preclinical testing on the drug candidate is strongly encouraged by early results demonstrated reduction of distal metastases.

Agilvax is also using its platform technology to develop vaccines against debilitating infectious diseases. The company's lead candidate is a next-generation HPV vaccine that holds the potential to provide protection a broader range of HPV subtypes than currently available vaccines. Infection with certain types of HPV, which there are over a 100, can lead to the formation of cervical cancers, as well as oropharyngeal and anogential cancers. Agilvax has created a broadly protective low-cost vaccine that is currently being aided by a collaboration with the NIH.

Agilvax is also working on the development of a vaccine against respiratory syncytial virus (RSV). RSV is a respiratory virus that infects the lungs and breathing passages that primarily impacts the world's most vulnerable populations; infants and the elderly. Agilvax was recently awarded a $286,000 Small Business Innovation Research (SBIR) grant to fund development of this vaccine program.

About the Platform

Agilvax's proprietary VLP platform technology, which is utilized for the discovery and development of cancer immunotherapies and vaccines stimulates robust and specific immune responses to self and foreign antigens. The platform allows the company to develop products through a unique affinity selection process, where candidates will stimulate an immune response that mimics the selecting antibody. Secondly, the platform also allows for the rational engineer and display of specific previously identified epitopes in a highly immunogenic form

HIGHLIGHTS

- Platform technology for cancer immunotherapy, vaccine discovery and development
- Strong Intellectual Property Portfolio
- Established collaborations with Government and Industry
- Founded in 2011
- Headquarters in Albuquerque, NM & offices in El Paso, TX
- Raised $3M in equity investment
- Received $286,000 SBIR grant

PIPELINE



TEAM

Federica Pericle, PhD, MBA
President and CEO
Michael Perrine, MS, MBA
Mitchell Tyler, PhD
John O' Rourke, PhD
Jayne Christen, PhD
Constance Dorian
Gabriela Aguilar

BOARD

Waneta Tuttle, PhD, MBA –Chairman
CEO Southwest Medical Ventures
Federica Pericle, PhD, MBA
President and CEO
Brad H. Vale, PhD, DVA
CEO of Calaveras Creek Capital and former Head of Johnson and Johnson Development Corporation
Faith L. Charles JD,
Partner in Thompson Hine's Corp. Transactions & Securities
Brian Birk
Managing Partner of Sun Mountain Capital
Ebetuel (Beto) Pallares, PhD
Joseph Advisory Services/ Hunt Holdings
Stuart Rose, PhD
Founder of The Bioscience Center and FatPipe BQ

ADVISORY BOARD

David Peabody, PhD
Professor, University of New Mexico
Bryce Chackerian, PhD
Associate Professor, University of New Mexico
Doug Watts, MS, PhD
Professor, University of Texas El Paso
Frank Borriello, MD, PhD Baxter, Shire, Takeda, Millenium
Enrico Braglia
OneLife, Helsinn